Znanstveni rad - Izvorni znanstveni rad
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
The Lancet Haematology, 10 (2023), 11; e879-e889. https://doi.org/10.1016/S2352-3026(23)00273-9

(ORTC Leukemia Group, GIMEMA, and German MDS Study Group) Lübbert, Michael; Wijermans, Pierre W; Kicinski, Michal; Chantepie, Sylvain; Van der Velden, Walter J F M; Noppeney, Richard; Griškevičius, Laimonas; Neubauer, Andreas; Crysandt, Martina; Vrhovac, Radovan; Luppi, Mario; Fuhrmann, Stephan; Audisio, Ernesta; Candoni, Anna; Legrand, Olivier; Foà, Robin; Gaidano, Gianluca; van Lammeren-Venema, Danielle; Posthuma, Eduardus F M; Hoogendoorn, Mels; Giraut, Anne; Stevens-Kroef, Marian; Jansen, Joop H; de Graaf, Aniek O; Efficace, Fabio; Ammatuna, Emanuele; Vilque, Jean-Pierre; Wäsch, Ralph; Becker, Heiko; Blijlevens, Nicole; Dührsen, Ulrich; Baron, Frédéric; Suciu, Stefan; Amadori, Sergio; Venditti, Adriano; Huls, Gerwin Više autora...

Citirajte ovaj rad

Lübbert, M., Wijermans, P. W., Kicinski, M., Chantepie, S., Van der Velden, W. J. F. M., Noppeney, R. ... Huls, G. (2023). 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. The Lancet Haematology, 10. (11), e879-e889. doi: 10.1016/S2352-3026(23)00273-9

Lübbert, Michael, et al. "10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial." The Lancet Haematology, vol. 10, br. 11, 2023, str. e879-e889. https://doi.org/10.1016/S2352-3026(23)00273-9

Lübbert, Michael, Pierre W Wijermans, Michal Kicinski, Sylvain Chantepie, Walter J F M Van der Velden, Richard Noppeney, Laimonas Griškevičius, et al. "10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial." The Lancet Haematology 10, br. 11 (2023): e879-e889. https://doi.org/10.1016/S2352-3026(23)00273-9

Lübbert, M., et al. (2023) '10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial', The Lancet Haematology, 10(11), str. e879-e889. doi: 10.1016/S2352-3026(23)00273-9

Lübbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, i sur.. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. The Lancet Haematology [Internet]. 11.2023. [pristupljeno 06.07.2024.];10(11):e879-e889. doi: 10.1016/S2352-3026(23)00273-9

M. Lübbert, et al., "10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial", The Lancet Haematology, vol. 10, br. 11, str. e879-e889, Studeni 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:992101. [Citirano: 06.07.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.